Life sciences company Avantor (NYSE:AVTR) fell short of the market’s revenue expectations in Q4 CY2024, with sales falling 2.1% year on year to $1.69 billion. Its non-GAAP profit of $0.27 per ...

Revenue: US$6.78b (down 2.6% from FY 2023). Net income: US$711.5m (up 122% from FY 2023). Profit margin: 11% (up from 4.6% in FY 2023). EPS: US$1.05 (up from US$0.47 in FY 2023). Revenue was in ...

Wells Fargo analyst Brandon Couillard maintained a Buy rating on Avantor (AVTR – Research Report) today and set a price target of $28.00. The company’s shares closed last Friday at $19.16.

Bernstein analyst Eve Burstein lowered the firm’s price target on Avantor (AVTR) to $22 from $24.50 and keeps a Market Perform rating on the shares following quarterly results. The firm says the ...

Michael Stubblefield, CEO, highlighted Avantor's return to growth in Q4 2024 with low single-digit organic growth and strong bioprocessing performance, achieving high single-digit organic growth ...

Avantor has a 12 month low of $19.59 and a 12 month high of $28.00. The stock has a 50 day moving average of $21.71 and a 200-day moving average of $23.47. The company has a market capitalization ...

(RTTNews) - Avantor, Inc (AVTR) released a profit for its fourth quarter that increased from the same period last year and beat the Street estimates. The company's earnings totaled $500.4 million ...

Avantor, Inc. has a fifty-two week low of $19.59 and a fifty-two week high of $28.00. The firm’s 50 day moving average price is $21.60 and its two-hundred day moving average price is $23.45.

5 analysts have expressed a variety of opinions on Avantor AVTR over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a concise overview of ...

Intercontinental Exchange and RELX are among the stocks that are now expensive. We sell different types of products and services to both investment professionals and individual investors. These ...

(RTTNews) - Avantor, Inc. (AVTR), a biotechnology, chemicals, and pharmaceuticals company, Friday announced a surge in net income for the fourth quarter, from the prior year. Shares of Avantor are ...

Performances in N.Y.C. Advertisement Supported by Once used to frequent rejection letters, Blue has become a regular on major stages and is singing the title role in “Aida” at the Metropolitan ...